@article{450b495fd8c841e784c37d278821111e,
title = "Defining the genetic susceptibility to cervical neoplasia - a genome-wide association study",
abstract = "A small percentage of women with cervical HPV infection progress to cervical neoplasia, and the risk factors determining progression are incompletely understood. We sought to define the genetic loci involved in cervical neoplasia and to assess its heritability using unbiased unrelated case/control statistical approaches. We demonstrated strong association of cervical neoplasia with risk and protective HLA haplotypes that are determined by the amino-acids carried at positions 13 and 71 in pocket 4 of HLA-DRB1 and position 156 in HLA-B. Furthermore, 36% (standard error 2.4%) of liability of HPV-associated cervical pre-cancer and cancer is determined by common genetic variants. Women in the highest 10% of genetic risk scores have approximately >7.1% risk, and those in the highest 5% have approximately >21.6% risk, of developing cervical neoplasia. Future studies should examine genetic risk prediction in assessing the risk of cervical neoplasia further, in combination with other screening methods.",
author = "Leo, {Paul J.} and Madeleine, {Margaret M.} and Sophia Wang and Schwartz, {Stephen M.} and Felicity Newell and Ulrika Kymmer and Kari Hemminki and Goran Hallmans and Sven Tiews and Winfried Steinberg and Rader, {Janet S.} and Felipe Castro and Mahboobeh Safaeian and Franco, {Eduardo L.} and Francois Coutlee and Claes Ohlsson and Adrian Cortes and Mhairi Marshall and Pamela Mukhopadhyay and Katie Cremin and Johnson, {Lisa G.} and Suzanne Garland and Tabrizi, {Sepehr N.} and Nicolas Wentzensen and Freddy Sitas and Julian Little and Maggie Cruickshank and Frazer, {Ian H.} and Allan Hildesheim and Brown, {Matthew A.}",
note = "Funding: MAB was funded by a National Health and Medical Research Council (Australia) Senior Principal Research Fellowship. Support was also received from the Australian Cancer Research Foundation. JL holds a Tier 1 Canada Research Chair in Human Genome Epidemiology. The Seattle study was supported by the following grants: NIH, National Cancer Institute grants P01CA042792 and R01CA112512. Cervical Health Study (from which the NSW component was obtained) was funded by NHMRC Grant 387701, and CCNSW core grant. The Montreal study was funded by the Canadian Institutes of Health Research (grant MOP-42532) and sample processing was funded by the Reseau FRQS SIDA-MI. The Swedish Research Council, the Swedish Foundation for Strategic Research, the ALF/LUA research grant in Gothenburg and Ume{\aa}, the Lundberg Foundation, the Torsten and Ragnar Soderberg{\textquoteright}s Foundation, the Novo Nordisk Foundation, and the European Commission grant HEALTH-F2-2008-201865-GEFOS, BBMRI.se, the Swedish Society of Medicine, the KempeFoundation (JCK-1021), the Medical Faculty of Ume{\aa} University, the County Council of Vasterbotten (Spjutspetsanslag VLL:159:33-2007). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript",
year = "2017",
doi = "10.1371/journal.pgen.1006866",
language = "English",
volume = "13",
journal = "PLoS Genetics",
issn = "1553-7390",
publisher = "Public Library of Science",
number = "8",
}